Rafael Pharmaceuticals Enrolls More Than 75% of Patients Needed for Pivotal Phase 3 Trial (AVENGER 500) of CPI-613®️ (devimistat) for Patients with Metastatic Pancreatic Cancer

COVID-19 task force established to support enrolled patients Participating medical centers implemented safety measures and currently enrolling patients Cranbury, NJ, March 24, 2020 (GLOBE NEWSWIRE) — Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a...
SEARCH FOR STUDIES